 |
市場調查報告書
商品編碼
1349941
造血幹細胞移植(HSCT)市場:各移植類型，各適應症，各用途，各終端用戶，各地區-規模，佔有率，展望，機會分析，2023年～2030年Hematopoietic stem cell transplantation market, By Transplant Type, By Indication, By Application, By End User, By Region -Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030 |
||||||
價格
簡介目錄
2023年全球造血幹細胞移植（HSCT）市場規模預估為28.8億美元，預測期間（2023-2030年）複合年增長率為11.2%。
| 報告範圍 | 報告詳細資料 | ||
|---|---|---|---|
| 基準年 | 2022 | 2023 年市場規模 | 美國：28.8億美元 |
| 過去的資料 | 2018年至2021年 | 預測期間 | 2023-2030 |
| 預測 2023-2030 年複合年增長率： | 11.20% | 2030年價值預測 | 60.5億美元 |
造血細胞移植（也稱為骨髓移植或幹細胞移植）是癌症（和其他一些疾病）的一種治療方法。確認骨髓的正常功能可能有助於了解幹細胞移植。造血細胞移植是治療癌症最有效的方法。其他治療，例如化療和放射治療，對骨髓有毒。一般來說，劑量越高，骨髓毒性越大。
造血細胞移植主要有兩種：自體移植和同種異體移植。在自體移植中，患者自身的造血幹細胞在大劑量化療或放療之前被取出，並冷凍保存以備後用。化療或放射治療結束後，收集的細胞被解凍並返回給患者。在同種異體移植中，造血幹細胞取自捐贈者，最好是具有相似基因組成的兄弟姊妹。
市場動態
增加有機成長策略，例如主要市場進入者推出產品以擴大其產品組合，預計將在預測期內推動市場成長。例如，2020年1月，基因治療產品提供者Bluebird Bio, Inc.推出了一項針對12歲及以上輸血依賴性熱貧血症（TDT）患者進行造血幹細胞（HSC）移植的一次性基因治療計畫。推出ZYNTEGLO（編碼Hui A-T87Q-珠蛋白基因的自體CD34+ 細胞）。ZYNTEGLO 的官方通用名稱是基因工程自體 CD34+ 細胞富集群，其中含有編碼 Hui A-T87Q-球蛋白基因的慢病毒載體轉導的造血幹細胞。
本調查的主要特徵
- 本報告提供以2022年為基準年的預測期間（2023-2030 年）之全球造血幹細胞移植(HSCT)市場的市場規模和復合年增長率（CAGR %）相關的詳區隔析。
- 並闡明不同部門市場的潛在收入機會，說明該市場具有魅力的投資主張矩陣。
- 同時並提供市場推動因素和限制、機會、新產品發布或批准、市場趨勢、區域前景和主要參與者採用的競爭戰略等重要考察。
- 並基於企業亮點，各類型投資組合、主要焦點、財務業績和市場策略等參數，介紹全球造血幹細胞移植(HSCT)市場的主要參與者之企業簡介。
- 藉由該報告提供的洞察，將能幫助營銷人員和公司高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。
- 全球造血幹細胞移植(HSCT)市場報告配合該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
- 利益相關者可以透過全球造血幹細胞移植(HSCT)市場用於分析的各種戰略矩陣來幫助他們更容易做下決策。
目錄
第1章 調查目的與前提條件
- 調查目的
- 前提條件
- 簡稱
第2章 市場概況
- 報告概要
- 市場定義和範圍
- 摘要整理
第3章 市場動態，法規，趨勢分析
- 市場動態
- 促進因素
- 阻礙因素
- 市場機會
- 影響分析
- 最近的檢驗藥上市
- 流行病學
- 合併，收購，聯盟
- 法規情勢
- 主要的發展
- PEST分析
第4章 全球造血幹細胞移植(HSCT)市場-COVID-19影響分析
- 經濟影響
- COVID-19流行病學
- 供需的影響
第5章 造血幹細胞移植(HSCT)的全球市場:各移植類型，2018年-2030年
- 同類移植
- 自體移植
第6章 造血幹細胞移植(HSCT)的全球市場:適應各疾病，2018年～2030年
- 急性骨髓性白血病(AML)
- 急性淋巴芽球性白血病(ALL)
- 何杰金氏淋巴瘤(HL)
- 非何杰金氏淋巴瘤(NHL)
- 多發性骨髓瘤(MM)
- 其他
第7章 造血幹細胞移植(HSCT)的全球市場，各用途，2018年～2030年
- 骨髓移植(BMT)
- 週邊血液幹細胞移植(PBSCT)
- 臍帶血移植(CBT)
第8章 造血幹細胞移植(HSCT)的全球市場:各終端用戶，2018年～2030年
- 醫院
- 專門診所
- 其他
第9章 造血幹細胞移植(HSCT)的全球市場:各地區，2018年～2030年
- 北美
- 美國
- 加拿大
- 南美
- 巴西
- 墨西哥
- 阿根廷
- 其他南美國家
- 歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲
- 亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太地區
- 中東
- GCC
- 以色列
- 其他中東
- 非洲
- 北非
- 中非
- 南非
第10章 競爭情形
- 企業簡介
- Pluristem Therapeutics Inc.
- CellGenix GmbH
- Regen Biopharma Inc.
- Lonza Group
- Kiadis Pharma
- Taiga Biotechnologies, Inc.
- Takeda Pharmaceutical Company Limited
- Escape Therapeutics, Inc.
- Bluebird Bio,Inc.
- Talaris Therapeutics, Inc.,
- Marker Therapeutics Inc.
- Stempeutics Research Pvt Ltd.
- CBR Systems Inc.
- Priothera Ltd.
- Eurobio Scientific Group
- Otsuka America Pharmaceutical, Inc.
- Pfizer Inc.
- Sanofi
- FUJIFILM Holdings Corporation
第11章 章節
- 參考文獻
- 調查手法
簡介目錄
Product Code: CMI1250
The global hematopoietic stem cell transplantation (HSCT) market is estimated to be valued at US$ 2.88 Billion in 2023 and is expected to exhibit a CAGR of 11.2% during the forecast period (2023-2030).
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2022 | Market Size in 2023: | US$ 2.88 Bn |
| Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
| Forecast Period 2023 to 2030 CAGR: | 11.20% | 2030 Value Projection: | US$ 6.05 Bn |
Hematopoietic cell transplantation (also called bone marrow transplantation or stem cell transplantation) is a type of treatment for cancer (and a few other conditions as well). A review of the normal function of the bone marrow will help in the understanding of stem cell transplantation. Hematopoietic cell transplantation is the most effective treatment for cancer. Other treatments, such as chemotherapy and radiation, are toxic to the bone marrow. In general, the higher the dose, the more toxic the effects on the bone marrow.
There are two main types of hematopoietic cell transplantation: autologous and allogeneic. In autologous transplantation, the patient's own hematopoietic stem cells are removed before high-dose chemotherapy or radiation is given, and they are then frozen for storage and later use. After chemotherapy or radiation is complete, the harvested cells are thawed and returned to the patient. In allogeneic transplantation, the hematopoietic stem cells come from a donor, ideally a brother or sister with a similar genetic makeup.
Market Dynamics
The increasing organic growth strategies, such as product launches by key market players to expand their product portfolio are expected to drive market growth over the forecast period. For instance, in January 2020, Bluebird Bio, Inc., a company providing gene therapy products, announced the launch of ZYNTEGLO (autologous CD34+ cells encoding βA-T87Q-globin gene), a one-time gene therapy for patients 12 years of age and older with transfusion-dependent β-thalassemia (TDT) for hematopoietic stem cell (HSC) transplantation in Germany. The full common name for ZYNTEGLO is a genetically modified autologous CD34+ cell-enriched population that contains hematopoietic stem cells transduced with a lentiviral vector encoding the βA-T87Q-globin gene.
Key features of the study:
- This report provides an in-depth analysis of the global hematopoietic stem cell transplantation (HSCT) market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global hematopoietic stem cell transplantation (HSCT) market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Pluristem Therapeutics Inc., CellGenix GmbH, Regen Biopharma Inc., Lonza Group, Kiadis Pharma, Taiga Biotechnologies, Inc., Takeda Pharmaceutical Company Limited, Escape Therapeutics, Inc., Bluebird Bio, Inc., Talaris Therapeutics, Inc., Marker Therapeutics Inc., Stempeutics Research Pvt Ltd., CBR Systems Inc., Priothera Ltd., Eurobio Scientific Group, Otsuka America Pharmaceutical, Inc., Pfizer Inc., Sanofi, FUJIFILM Holdings Corporation
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global hematopoietic stem cell transplantation (HSCT) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hematopoietic stem cell transplantation (HSCT) market
Detailed Segmentation:
- Global Hematopoietic Stem Cell Transplantation (HSCT) Market , By Transplant Type:
- Allogeneic
- Autologous
- Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Indication:
- Acute Myeloid Leukemia (AML)
- Acute Lymphoblastic Leukemia (ALL)
- Hodgkin lymphoma (HL)
- Non-Hodgkin Lymphoma (NHL)
- Multiple Myeloma (MM)
- Others
- Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Application:
- Bone Marrow Transplant (BMT)
- Peripheral Blood Stem Cells Transplant (PBSCT)
- Cord Blood Transplant (CBT)
- Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By End User:
- Hospitals
- Specialty Clinics
- Others
- Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Region:
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Pluristem Therapeutics Inc.
- CellGenix GmbH
- Regen Biopharma Inc.
- Lonza Group
- Kiadis Pharma
- Taiga Biotechnologies, Inc.
- Takeda Pharmaceutical Company Limited
- Escape Therapeutics, Inc.
- Bluebird Bio, Inc.
- Talaris Therapeutics, Inc.
- Marker Therapeutics Inc.
- Stempeutics Research Pvt Ltd.
- CBR Systems Inc.
- Priothera Ltd.
- Eurobio Scientific Group
- Otsuka America Pharmaceutical, Inc.
- Pfizer Inc.
- Sanofi
- FUJIFILM Holdings Corporation
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Transplant Type
- Market Snippet, By Indication
- Market Snippet, By Application
- Market Snippet, By End User
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Test Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
4. Global Hematopoietic Stem Cell Transplantation (HSCT) Market- COVID-19 Impact Analysis
- Economic Impact
- COVID-19 Epidemiology
- Impact on Supply and Demand
5. Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Transplant Type, 2018- 2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Allogeneic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018- 2030, (US$ Bn)
- Autologous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018- 2030, (US$ Bn)
6. Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Indication, 2018 - 2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Acute Myeloid Leukemia (AML)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018- 2030, (US$ Bn)
- Acute Lymphoblastic Leukemia (ALL)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018- 2030, (US$ Bn)
- Hodgkin lymphoma (HL)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018- 2030, (US$ Bn)
- Non-Hodgkin Lymphoma (NHL)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018- 2030, (US$ Bn)
- Multiple Myeloma (MM)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018- 2030, (US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018- 2030, (US$ Bn)
7. Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Application, 2018 - 2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Bone Marrow Transplant (BMT)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018- 2030, (US$ Bn)
- Peripheral Blood Stem Cells Transplant (PBSCT)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018- 2030, (US$ Bn)
- Cord Blood Transplant (CBT)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018- 2030, (US$ Bn)
8. Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By End User, 2018 - 2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018- 2030, (US$ Bn)
- Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018- 2030, (US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018- 2030, (US$ Bn)
9. Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Region, 2018 - 2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- North America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Transplant Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2018 -2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Application, 2018-2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By End User, 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Transplant Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2018 -2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Application, 2018-2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By End User, 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Transplant Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2018 -2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Application, 2018-2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By End User, 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Transplant Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2018 -2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Application, 2018-2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By End User, 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Transplant Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2018 -2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Application, 2018-2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By End User, 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Transplant Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2018 -2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Application, 2018-2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By End User, 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country/Region, 2018 -2030, (US$ Bn)
- North Africa
- Central Africa
- South Africa
10. Competitive Landscape
- Company Profiles
- Pluristem Therapeutics Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- CellGenix GmbH
- Regen Biopharma Inc.
- Lonza Group
- Kiadis Pharma
- Taiga Biotechnologies, Inc.
- Takeda Pharmaceutical Company Limited
- Escape Therapeutics, Inc.
- Bluebird Bio,Inc.
- Talaris Therapeutics, Inc.,
- Marker Therapeutics Inc.
- Stempeutics Research Pvt Ltd.
- CBR Systems Inc.
- Priothera Ltd.
- Eurobio Scientific Group
- Otsuka America Pharmaceutical, Inc.
- Pfizer Inc.
- Sanofi
- FUJIFILM Holdings Corporation
11. Section
- References
- Research Methodology
- About us and Sales Contact
